| Literature DB >> 34870113 |
Fatma Nur Kesiktaş1, Erdem Kaşıkçıoğlu2, Nurdan Paker1, Bülent Bayraktar2, Ayşe Karan3, Ayşegül Ketenci3, Lütfiye Müslümanoğlu3.
Abstract
OBJECTIVES: The aim of this study was to compare the efficacy of home-based upper extremity circuit training exercises (CTEs) with supervised hospital program in male patients with traumatic complete paraplegia. PATIENTS AND METHODS: Twenty men with paraplegia (mean age: 38±10.1 years; range, 30 to 43 years) between January 2007 and November 2007 were randomized into two groups. The first group had supervised hospital CTE program, whereas the second group had home-based CTE. The effects of the upper extremity CTE by using elastic bands 60 min per day, five days a week, for a total of eight weeks (70% maximal oxygen consumption [VO2max]) were examined. The Cybex was used for the isokinetic testing of the upper extremities. The VO2max and maximum heart rate (HR) were assessed using an arm ergometer. The Craig Handicap Report Technique Short Form (CHART-SF) was used for the evaluation of functional independence and mobility. Serum lipid profiles were measured.Entities:
Keywords: Exercise; male; maximal oxygen consumption; paraplegia; spinal cord injury; upper extremity; wheelchair
Year: 2021 PMID: 34870113 PMCID: PMC8606995 DOI: 10.5606/tftrd.2021.6533
Source DB: PubMed Journal: Turk J Phys Med Rehabil ISSN: 2587-1250
Demographic and clinical characteristics of patients
| Hospital group (n=10) | Home group (n=10) | ||||||||
| n | % | Median | IQR | n | % | Median | IQR | ||
| Age (year) | 35 | 30-43 | 36 | 32-41 | U=34; p=0.223 | ||||
| SCI duration (year) | 8 | 7-9.2 | 7.8 | 7-9.3 | U=49.5; p=0.968 | ||||
| Height (cm) | 170 | 1.65-180 | 175 | 169-181 | U=35; p=0.250 | ||||
| Weight (kg) | 70 | 68-80 | 68.5 | 66.5-81 | U=45; p=0.729 | ||||
| Married | 5 | 50 | 5 | 50 | χ2=0; p=1 | ||||
| Levels T4-6 | 3 | 30 | 2 | 20 | χ2=0.2; p=0.905 | ||||
| T7-9 | 3 | 30 | 4 | 40 | |||||
| T10-12 | 4 | 40 | 4 | 40 | |||||
| IQR: Interquartile range; U: Mann-Whitney U test; χ2: Fisher exact test. | |||||||||
Differences in shoulder and elbow flexor and extensor peak torque values at the end of treatment
| Hospital group | Home group | ||||||||
| Baseline | End | Baseline | End | Between groups | |||||
| Peak torque (Nm) | Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| Right shoulder extension | 65 | 58-71 | 69.5 | 60-72 | 65.5 | 57-71 | 71 | 59-72 | U=44; p=0.935 |
| z=-2.103 | *p=0.035 | z=-2.380 | *p=0.017 | ||||||
| Left shoulder extension | 62.5 | 60-70 | 72 | 64-78 | 61 | 55-69 | 71 | 64-77 | U=33; p=0.326 |
| z=-2.553 | *p=0.01 | z=-2.442 | *p=0.015 | ||||||
| Right shoulder flexion | 49 | 46-59 | 52 | 49-59 | 48 | 45-60 | 54 | 50-61 | U=32; p=0.283 |
| z=-1.951 | p=0.05 | z=-2.371 | *p=0.018 | ||||||
| Left shoulder flexion | 47 | 44-58 | 52 | 49-59 | 46 | 43-58 | 52 | 49-58 | U=43.5; p=0.902 |
| z=-2.677 | *p=0.007 | z=-2.379; | *p=0.017 | ||||||
| Right elbow extension | 42 | 39-49 | 50 | 43-58 | 44 | 40-49 | 52 | 45-57 | U=42.0; p=0.806 |
| z=-2.666 | *p=0.008 | z=-2.66 | *p=0.008 | ||||||
| Left elbow extension | 40 | 37-46 | 50 | 43-57 | 43 | 39-48 | 51 | 44-57 | U=34.5; p=0.390 |
| z=-2.807 | *p=0.005 | z=-2.52 | *p=0.012 | ||||||
| Right elbow flexion | 37 | 34-41 | 42 | 38-48 | 37 | 33-42 | 43 | 38-49 | U=37.0; p=0.511 |
| z=-2.677 | *p=0. 007 | z=-2.37 | *p=0.018 | ||||||
| Left elbow flexion | 37 | 35-41 | 41 | 37-48 | 38 | 34-42 | 46 | 41-52 | U=24.5; p=0.091 |
| z=-2.556 | *p=0. 011 | z=-2.66 | *p=0.008 | ||||||
| IQR: Interquartile range; z: Wilcoxon signed-rank test; U: Mann-Whitney U test; * p<0.05. | |||||||||
Differences in VO2max and maximum heart rate at the end of treatment
| Hospital group | Home group | ||||||||
| Baseline | End | Baseline | End | Between groups | |||||
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | ||
| VO2max (mL/kg/min) | 16.5 | 15-19 | 24 | 21-27 | 15.5 | 14-17.5 | 19 | 17-22 | U=14.5; **p=0.012 |
| z=2.814 | *p=0.005 | z=2.499 | *p=0.012 | ||||||
| Max HR (beat/min) | 173 | 164-185 | 150.5 | 145-163 | 167 | 162-180 | 145 | 140-152 | U=30; p=0.220 |
| z=2.807 | *p=0.005 | z=2.192 | *p=0.028 | ||||||
Differences in CHART-SF at the end of treatment
| Hospital group | Home group | ||||||||
| Baseline | End | Baseline | End | Between groups | |||||
| CHART SF domains | Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| Independence | 47 | 40-58 | 57 | 50-67 | 64 | 54-73 | 67 | 59-76 | U=20.5; **p=0.039 |
| z=2.53 | p=0.011 | z=1.84 | p=0.06 | ||||||
| Function in society | 47 | 37-58 | 51 | 44-60 | 51 | 42-58 | 54 | 43-61 | U=38; p=0.545 |
| z=2.232 | p=0.026 | z=1.84 | p=0.06 | ||||||
| Mobility | 46 | 38-54 | 54 | 44-63 | 56 | 47-63 | 58 | 50-66 | U=16; **p=0.016 |
| z=2.03 | *p=0.04 | z=1.84 | p=0.06 | ||||||
| Ability to work | 33 | 23-44 | 36 | 23-48 | 40 | 31-48 | 42 | 31-49 | U=34; p=0.337 |
| z=2.242 | p=0.025 | z=1.604 | p=1.09 | ||||||
| Socialize | 77 | 70-85 | 79 | 70-86 | 83 | 79-89 | 83 | 79-89 | U=36; p=0.168 |
| z=1.34 | p=0.18 | z=0.00 | p=1 | ||||||
| CHART-SF: Craig Handicap Assessment and Reporting Technique Short Form; IQR: Interquartile range; z: Wilcoxon signed-rank test; U: Mann-Whitney U test; * p<0.05; ** p<0.05. | |||||||||
Differences in serum lipid profile at the end of treatment
| Hospital group | Home group | ||||||||
| Baseline | End | Baseline | End | Between groups | |||||
| Lipids (mg/dL) | Median | IQR | Median | IQR | Median | IQR | Median | IQR | p |
| Total cholesterol | 178 | 160-218 | 144 | 138-168 | 204 | 175-230 | 169 | 150-178 | U=44; p=0.935 |
| z=2.497 | *p=0.013 | z=2.192 | *p=0.028 | ||||||
| Triglyceride | 105 | 95-155 | 100 | 92-150 | 101 | 95-150 | 100 | 92-150 | U=41; p=0.744 |
| z=1.122 | p=0.262 | z=1.140 | p=0.889 | ||||||
| HDL-C | 22 | 20-25 | 27 | 24-31 | 25 | 20-30 | 30 | 25-40 | U=33.5; p=0.462 |
| z=-2.803 | *p=0.005 | z=-2.386 | *p=0.017 | ||||||
| LDL-C | 122 | 110-155 | 107 | 95-130 | 134 | 124-154 | 114 | 100-128 | U=36; p=0.462 |
| z=1.580 | p=0.114 | z=1.481 | p=0.139 | ||||||
| IQR: Interquartile range; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; z: Wilcoxon signed-rank test; U: Mann-Whitney U test; * p<0.05; ** p<0.05. | |||||||||